Indivior (NASDAQ:INDV – Get Free Report) is one of 867 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Indivior to similar businesses based on the strength of its valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and profitability.
Profitability
This table compares Indivior and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Indivior | N/A | N/A | N/A |
| Indivior Competitors | -2,450.93% | -895.40% | -32.23% |
Volatility and Risk
Indivior has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Indivior’s competitors have a beta of 0.77, indicating that their average share price is 23% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Indivior | 0 | 0 | 1 | 0 | 3.00 |
| Indivior Competitors | 4458 | 14772 | 38080 | 691 | 2.60 |
Indivior currently has a consensus price target of $35.00, indicating a potential upside of 45.05%. As a group, “Pharmaceutical preparations” companies have a potential upside of 107.36%. Given Indivior’s competitors higher possible upside, analysts clearly believe Indivior has less favorable growth aspects than its competitors.
Valuation & Earnings
This table compares Indivior and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Indivior | $947.00 million | $205.00 million | 22.98 |
| Indivior Competitors | $10.16 billion | $175.90 million | -1.12 |
Indivior’s competitors have higher revenue, but lower earnings than Indivior. Indivior is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
0.1% of Indivior shares are held by institutional investors. Comparatively, 40.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Indivior beats its competitors on 7 of the 13 factors compared.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
